LASERS IN THE TREATMENT OF HEART DISEASE IN NEONATES

Information

  • Research Project
  • 2421955
  • ApplicationId
    2421955
  • Core Project Number
    R43HL059062
  • Full Project Number
    1R43HL059062-01
  • Serial Number
    59062
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/15/1997 - 27 years ago
  • Project End Date
    1/14/1998 - 27 years ago
  • Program Officer Name
  • Budget Start Date
    7/15/1997 - 27 years ago
  • Budget End Date
    1/14/1998 - 27 years ago
  • Fiscal Year
    1997
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/15/1997 - 27 years ago

LASERS IN THE TREATMENT OF HEART DISEASE IN NEONATES

DESCRIPTION (Adapted from applicant's abstract): Increasingly complex neonatal cardiac repairs are being performed on younger and younger infants with greater success. Yet as treatment runs closer to what is tolerable to the body, smaller details become major determinants of success. Two outstanding independent variables are associated with poorer outcome; excess hemorrhage and prolonged operative time, particularly cardiopulmonary bypass time. Excess hemorrhage requires excess blood transfusion with the risks of infectious agent transmittal and hemostatic and metabolic insult to the neonate. Long bypass times produce more pronounced inflammatory responses by the host with secondary organ dysfunction. The ability to minimize these factors will increase the safety of the operation and will significantly reduce expenses such as ICU, hospital stays and blood product costs. Recent advances in laser technology may provide this improvement in hemostasis and thereby reduce the operation time. This project will study the impact of laser activated hemostatic methods on conventional anastomotic techniques as well as laser welding methods developed previously by the research team. Phase I will include both in vitro and in vivo experiments. Spectroscopic measurements on neonatal tissue will guide the selection of the laser wavelength. Both temperature and optical feedback techniques developed under the CEE/LLNL CRADA will be used for controlling the laser to promote strong tissue bonds. Tissue solders or patches will be evaluated to enhance tissue welding and hemostasis. Phase II will focus on sensor control of the laser and will be based on neonatal tissue signature change at the welding endpoint. The subsequent development of a reliable tissue welding system will provide the bond strength and the ability to grow rapidly as required in the neonate.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    CONVERSION ENERGY ENTERPRISES
  • Organization Department
  • Organization DUNS
  • Organization City
    SPRING VALLEY
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    10977
  • Organization District
    UNITED STATES